ArticleBiofabrication2022
Biofabrication of 3D breast cancer models for dissecting the cytotoxic response of human T cells expressing engineered MAIT cell receptors.
Article in Biofabrication, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 26 citations in OpenAlex.
- 3D bioprinting for cancer modeling and drug screening.Biomarker research · 2026Review
- 3D Bioprinting for Tumor Microenvironment Reconstruction: Advances, Challenges, and Future Perspectives.Biotechnology journal · 2026Review
- Review
- Aspiration-assisted bioprinting of spheroids.Nature protocols · 2026Review
- 3D bioprinting innovations: a new frontier in breast cancer research.Medical oncology (Northwood, London, England) · 2025Review
- Mucosal-Associated Invariant T Cells: Origins, Biological Functions, Diseases, and Therapeutic Targets.MedComm · 2025Review
- 3D Bioprinting and Artificial Intelligence for Tumor Microenvironment Modeling: A Scoping Review of Models, Methods, and Integration Pathways.Molecular pharmaceutics · 2025Article
- Biofabrication of HepG2 Cells-Laden 3D Structures Using Nanocellulose-Reinforced Gelatin-Based Hydrogel Bioinks: Materials Characterization, Cell Viability Assessment, and Metabolomic Analysis.ACS biomaterials science & engineering · 2025Article
- Modeling intratumor heterogeneity in breast cancer.Biofabrication · 2024Review
- Nested Biofabrication: Matryoshka-Inspired Intra-Embedded Bioprinting.Small methods · 2024Article
- Embedded 3D bioprinting - An emerging strategy to fabricate biomimetic & large vascularized tissue constructs.Bioactive materials · 2024Review
- Mucosal-associated invariant T cells in cancer: dual roles, complex interactions and therapeutic potential.Frontiers in immunology · 2024Review
- Recent advances in 3D bioprinted tumor models for personalized medicine.Translational oncology · 2023Article
- Review
- The third dimension of tumor microenvironment-The importance of tumor stroma in 3D cancer models.Experimental biology and medicine (Maywood, N.J.) · 2023Review
- Mucosal-associated invariant T cells for cancer immunotherapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2023Review
- Editorial: Innovative 3D technologies in cancer immunity research and therapy.Frontiers in immunology · 2023Article
- Opportunities and challenges to engineer 3D models of tumor-adaptive immune interactions.Frontiers in immunology · 2023Review
- 3D bioprinting and the revolution in experimental cancer model systems-A review of developing new models and experiences withPathology oncology research : POR · 2023Review
- Engineering next-generation organoids: A review on bioprinting strategies, bioink innovations, and frontier applications.Journal of tissue engineeringReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
Abstract
Immunotherapy has revolutionized cancer treatment with the advent of advanced cell engineering techniques aimed at targeted therapy with reduced systemic toxicity. However, understanding the underlying immune-cancer interactions require development of advanced three-dimensional (3D) models of human tissues. In this study, we fabricated 3D tumor models with increasing complexity to study the cytotoxic responses of CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.